Core Viewpoint - The forecast for Chaoyang Yongxu's quarterly performance indicates a projected revenue range of 239.29 to 344.13 billion yuan, with a year-on-year change of -12.9% to 25.2%, and a net profit forecast of 11.29 to 16.21 billion yuan, reflecting a year-on-year change of -24.8% to 7.9% [1][6] Revenue and Profit Forecast - The predicted revenue range is 2392.99 to 3441.27 billion yuan, with a year-on-year change of -12.9% to 25.2% [1][2] - The forecasted net profit is between 112.93 and 162.08 billion yuan, with a year-on-year change of -24.8% to 7.9% [1][2] - The adjusted net profit is expected to be 148.51 billion yuan [1][2] Performance Analysis by Securities Firms - Various securities firms have provided differing forecasts, with the average revenue estimate at 286.34 billion yuan, showing a year-on-year increase of 4.2% [2][7] - The median revenue forecast is 281.78 billion yuan, reflecting a year-on-year increase of 2.5% [2][7] - Specific firms like Guohai Securities and Zhongjin Securities have provided individual estimates, with Guohai predicting a revenue of 288.67 billion yuan and Zhongjin forecasting 131.70 billion yuan in net profit [2][7] BYD Sales Insights - BYD's sales in January 2026 showed a year-on-year decline of 30.1%, but overseas sales increased by 51.5%, accounting for 48% of total sales [4][9] - The high-end strategy is progressing, with the Fangchengbao series achieving a significant year-on-year sales increase of 247% [4][9] - BYD is entering a "large battery hybrid" era, launching multiple new models aimed at consolidating market share through technological innovation [4][9] Overall Market Expectations - BYD's total sales for 2026 are projected to reach 5.12 million units, representing an 11% year-on-year increase, with exports expected to be between 1.5 to 1.6 million units, reflecting a growth of 44% to 53% [5][10] - The domestic sales are expected to remain stable, while high-end sales in January reached 28,000 units, marking a year-on-year increase of 54% [5][10] - The battery installation volume in January increased by 30%, with expectations of approximately 80 GWh in energy storage battery shipments for 2026 [5][10]

Core Insights - Roche announced that its oral BTK inhibitor Fenebrutinib achieved the primary endpoint in the pivotal Phase III study (FENhance 1) for relapsing multiple sclerosis (RMS) [1][6] - This marks the completion of all three pivotal Phase III studies for Fenebrutinib in the multiple sclerosis (MS) field [2][8] Efficacy Results - The FENhance 1 study demonstrated a significant reduction in annualized relapse rate (ARR) by 51% compared to the active control drug teriflunomide over a treatment period of at least 96 weeks, consistent with the results from the previously published FENhance 2 study, which showed a 59% reduction in ARR [3][9] - Combined data from both studies indicate that patients treated with Fenebrutinib experience a relapse on average every 17 years, showcasing strong disease control capabilities [4][10] Secondary Endpoints and Safety - Both RMS studies showed statistically significant and clinically meaningful effects of Fenebrutinib in reducing brain lesions (MRI lesions) [4][10] - All disease progression-related endpoints, including the composite confirmed disability progression at 12 and 24 weeks (cCDP), indicated favorable trends for Fenebrutinib [4][10] - The overall tolerability of Fenebrutinib was good, with liver enzyme elevations comparable to the control drug teriflunomide, and only one case of asymptomatic and reversible Hy's Law observed in each treatment group [4][10] - Notably, there were 8 deaths of various causes reported in the Fenebrutinib group across the two RMS studies, compared to 1 in the control group, prompting further investigation by Roche to clarify the reasons [4][10] Drug Profile and Future Plans - Fenebrutinib is a non-covalent, reversible, and highly selective BTK inhibitor designed to target both the peripheral and central nervous systems, addressing both acute inflammation and chronic damage driving long-term disability progression [5][11] - Roche's Chief Medical Officer, Dr. Levi Garraway, stated that the key study results, combined with early data, provide strong evidence that Fenebrutinib could become the first high-efficacy oral therapy for both relapsing (RMS) and primary progressive multiple sclerosis (PPMS) [5][11] - Roche plans to present the complete data from the FENhance 1, FENhance 2, and FENtrepid studies at the 2026 American Academy of Neurology (AAN) annual meeting and submit it to regulatory authorities [5][11]

Group 1: Chery Group - Chery Group sold 160,765 vehicles in February, with Chery brand sales at 146,173 units [4][19] - The cumulative export of Chery Group has surpassed 6 million units, maintaining over 100,000 units in exports for 10 consecutive months, and achieving an additional million units in exports over the past 8 months [4][19] Group 2: BYD - BYD's sales in February reached 190,190 units, with passenger vehicle sales at 187,782 units and overseas sales of passenger vehicles and pickups at 100,151 units, marking a year-on-year increase of 41.4% [5][19] - In the first two months, BYD's cumulative sales totaled 400,241 units, with overseas sales of passenger vehicles and pickups at 200,160 units [21] Group 3: Great Wall Motors - Great Wall Motors sold 72,594 new vehicles in February, with overseas sales increasing by 37.36% year-on-year [9][22] - The total sales for the first two months reached 162,906 units, reflecting a year-on-year growth of 2.58% [22][28] - Specific brand performances include Haval brand sales of 43,660 units, WEY brand sales of 5,615 units (up 54.13%), and Tank brand sales of 10,036 units [14][28] Group 4: Geely Automobile - Geely Automobile's sales in February amounted to 206,160 units, with new energy vehicle sales at 117,488 units, representing 57% of total sales [15][29] - The overseas export sales saw a significant increase of 138% year-on-year [15][29] - Geely brand sales were 154,934 units, with Lynk & Co brand sales at 27,359 units and Zeekr brand sales at 23,867 units, showing a year-on-year growth of 70% [15][29]

Group 1 - Agricultural Bank of China announced the dividend distribution plan for its preferred shares "Agricultural Bank Preferred 2" for the fiscal year 2025-2026, approved by the board meeting on February 13, 2026 [1][4][6] - The dividend is calculated at a nominal dividend rate of 3.77%, resulting in a cash dividend of RMB 3.77 per share (tax included), totaling RMB 1.508 billion (tax included) [1][4][8] - The dividend payment date is set for March 11, 2026, with the last trading day on March 9, 2026, and the ex-dividend date on March 10, 2026 [8]

Group 1 - GAC Group announced a production volume of 90,200 vehicles in February 2026, representing a year-on-year decrease of 14.88% [1] - The sales volume for February 2026 was 86,500 vehicles, down 12.43% year-on-year [1] - Cumulative production for the year reached 201,000 vehicles, a decline of 9.59% compared to the previous year, while cumulative sales were 203,100 vehicles, showing a year-on-year increase of 3.00% [1] Group 2 - The performance of the joint venture segment showed divergence, with GAC Toyota's production in February at 42,900 vehicles, a slight increase of 0.77% year-on-year, and sales of 41,500 vehicles, up 15.28% year-on-year [1] - In contrast, GAC Honda's production was 7,909 vehicles, down 61.95% year-on-year, and sales were 9,220 vehicles, reflecting a decline of 68.93% year-on-year [1]

3月2日金融一线消息，据国家金融监督管理总局佛山监管分局行政处罚信息公示列表显示，招商银行股 份有限公司佛山分行因个人经营性贷款"三查"不到位、并购贷款资金监控不到位，被罚款60万元。同 时，林浩然、鲁颖添因个人经营性贷款"三查"不到位、并购贷款资金监控不到位被给予警告。 | 序 島 | 当事人名 称 | 主要违法违规行为 | 行政处罚内容 | 作出决定机关 | | --- | --- | --- | --- | --- | | | 招商银行 | | 对招商银行佛 山分行罚款60 | 国家金融监督 | | | 股份有限 | 个人经营性贷款"三查"不到 | | | | 1 | 公司佛山 | 位、并购贷款资金监控不到位 | 万元,对林浩 | 管理总局佛山 | | | | | 然、鲁颖添给 | 监管分局 | | | 分行 | | 予警告。 | | 责任编辑：秦艺 3月2日金融一线消息，据国家金融监督管理总局佛山监管分局行政处罚信息公示列表显示，招商银行股 份有限公司佛山分行因个人经营性贷款"三查"不到位、并购贷款资金监控不到位，被罚款60万元。同 时，林浩然、鲁颖添因个人经营性贷款"三查"不到位、并购贷款资金监控不 ...

Core Viewpoint - The metal market is currently in a state of tight supply-demand balance, with macroeconomic factors being the key drivers of metal price trends, including monetary policy, macro expectations, geopolitical dynamics, and supply disruptions [1][12]. Precious Metals - Geopolitical disturbances, particularly the US-Iran conflict, have led to a steady increase in precious metal prices, supported by ongoing central bank gold purchases. As of the end of January, China's gold reserves reached 74.19 million ounces, an increase of 40,000 ounces from the previous month, marking 15 consecutive months of reserve expansion [2][13]. - Specific price movements include SHFE gold rising by 3.29% to 1,147.90 CNY per gram, COMEX gold increasing by 4.24% to 5,296.40 USD per ounce, and London gold rising by 3.27% to 5,278.26 USD per ounce. Silver prices also saw significant increases, with SHFE silver up 16.34% to 23,019 CNY per kilogram [2][13]. - Recommended stocks in the precious metals sector include Zhongjin Gold, Chifeng Jilong Gold, Shandong Gold, and Zhaojin Mining [3][14]. Base Metals - The copper sector is characterized by a strong supply-demand dynamic, with prices supported by strategic stockpiling and rigid supply. Recent data shows SHFE copper prices increased by 3.53% to 103,920 CNY per ton, while LME copper rose by 2.93% to 13,343.5 USD per ton [4][15]. - In contrast, the aluminum sector faces a "macro positive, inventory pressure" scenario, with SHFE aluminum prices rising by 2.76% to 23,835 CNY per ton, but facing seasonal supply pressures and increasing inventories [5][16]. - Recommended stocks for copper include Jincheng Resources and Luoyang Molybdenum, while for aluminum, recommended stocks include Yun Aluminum and Tianshan Aluminum [4][5][15][16]. Energy Metals - The energy metals sector is experiencing strong demand and declining inventories, with lithium carbonate continuing to deplete. Recommended stocks include Ganfeng Lithium and Tianqi Lithium [7][19]. - The cobalt sector is facing tight raw material supplies, with companies extending their operations into downstream electric new energy sectors to enhance competitive advantages. Recommended stocks include Huayou Cobalt [7][19]. Rare Earth and Strategic Metals - The rare earth sector has seen price increases post-holiday, with prices for praseodymium-neodymium oxide and dysprosium oxide rising significantly. The report highlights the investment value of rare earths as strategic resources [8][20]. - The tungsten sector is benefiting from supply constraints and strategic pricing models, with recommended stocks including Xiamen Tungsten [8][20]. - The uranium sector has seen long-term price increases due to supply rigidity and nuclear power development, with recommended stocks including China Uranium [9][21].

Core Viewpoint - ARK Invest predicts that Nvidia will face increasing competition in the coming years, with custom AI chips expected to capture over one-third of the computing market by 2030 [1] Group 1: Competitive Landscape - Nvidia is anticipated to encounter intensified competition as companies like Google position their Tensor Processing Units (TPUs) as alternatives to Nvidia's GPUs [1] - Meta has reportedly agreed to lease TPUs for advanced AI development, indicating a shift towards alternative solutions in the AI chip market [1]

Core Viewpoint - A case of misinformation regarding a well-known tea beverage brand claiming its caffeine content is akin to "quasi-drugs" has been resolved by law enforcement, emphasizing the importance of accurate information in consumer products [1][2] Group 1: Incident Overview - The Shanghai Changning Public Security Bureau has cracked a case involving a netizen named Ren, who falsely claimed that a popular tea brand's caffeine content was "quasi-drugs" to gain attention on social media [1] - The misleading comment was widely shared, causing significant consumer confusion, prompting a response from relevant authorities to clarify the safety standards of caffeine in beverages [1][2] Group 2: Official Responses - The Shanghai Anti-Drug Office issued a statement refuting the claims, asserting that caffeine in market beverages is derived from natural sources or compliant additives, with strict safety standards in place [2] - The tea brand, Bawang Chajiji, responded by comparing the caffeine content of its tea to that of a latte, indicating that it is significantly lower than that of an Americano, and has initiated legal proceedings to protect its rights [2]

(本文来自第一财经) 3月2日，小马智行回应第一财经，由于地区局势，为配合当地相关部门统一部署，保障测试安全，公司 此前暂停了迪拜和多哈的Robotaxi道路测试。经评估，多哈测试已于今日恢复。公司将继续与迪拜监管 机构保持沟通，在确保安全后适时恢复测试。（第一财经记者 黄琳） ...